Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.
Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara). The company’s lead candidate, AVT02 (a biosimilar to adalimumab), is being developed in collaboration with Teva Pharmaceuticals and has received marketing approval in several regions. Additional programs in late‐stage development aim to replicate therapies used across autoimmune disorders and cancer treatment, underscoring Alvotech’s focus on high‐value therapeutic areas.
Headquartered in Reykjavík, Iceland, Alvotech operates state‐of‐the‐art facilities that integrate research, development and large‐scale manufacturing under one roof. The company has also established regulatory and commercial partnerships to support product launches in key markets, including the United States, Europe and select Asia‐Pacific territories. This global footprint enables Alvotech to align its clinical development plans with regional regulatory requirements while optimizing supply chain logistics for commercial distribution.
Alvotech’s leadership team is led by Founder and Executive Chairman Robert Wessman, a biopharmaceutical entrepreneur with decades of industry experience. Under his guidance, the company has expanded its scientific capabilities and forged strategic alliances to advance its biosimilar portfolio. Supported by a management team with expertise in biologics development, regulatory affairs and global commercialization, Alvotech is positioned to play a significant role in increasing patient access to affordable biologic therapies.
AI Generated. May Contain Errors.
Free ALVO Stock Alerts